echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > Nat Med: Multi-clone and tendental antibody reaction of Ebola virus vaccine rVSV-ZEBOV.

    Nat Med: Multi-clone and tendental antibody reaction of Ebola virus vaccine rVSV-ZEBOV.

    • Last Update: 2020-07-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    the !---- recombinant bubbly oral inflammatory virus, the Zaire Ebola virus (rVSV-ZEBOV), is the most advanced candidate vaccine for the Ebola virus and is currently being used to fight the outbreak of Ebola virus disease (EVD) in the Democratic Republic of the Congo (DRC).here, we studied the body fluid immune response of a subset of human volunteers participating in the phase 1 rVSV-ZEBOV vaccination trial through a comprehensive analysis of single-B cells and electron microscopy structures.four of the subjects showed polyclonal, but repeatable and convergent B-cell reactions with common sequence characteristics.EBOV-targeted antibodies cross-react with other Ebola virus species, and a detailed epitope map shows that the target table overlaps with antibodies isolated from EVD survivors.in addition, among all vaccinators, we detected high-potency EBOV neutralizing antibodies that were as active or better as monoclonal antibodies used in current clinical trials.these antibodies include antibodies binding to the IGHV3-15/IGLV1-40 immunoglobulin gene segment, which were found in all the individuals surveyed.in summary, our findings will help to assess and guide current and future vaccination strategies and provide opportunities for new EVD therapies..
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.